 |
 |
Did anyone else receive an e-mail like this? Roberta From time to time, neurologists, caregivers, and MSA or Parkinson’s disease sufferers, their friends and families, provide us with the addresses of those they believe may be interested in receiving our research updates and newsletters on Neuronal Regeneration. (Also called Neurogenesis). They have noticed that our research project presents innovative approaches to treat a number of neurodegenerative disorders. They have also observed a direct improvement in MSA and PD patients who are following our Neurogenic Intervention Programme. They would like to share research results, in order to substantiate the evidence and rationale behind the use of neurogenic intervention programmes. Further research in neuroscience, clinical data and medical reports are required. Please let us know if you are interested in this subject and if you would like to receive or contribute with information about this specific type of research. We apologise if the above subject is not one of your particular concern. If this is the case, please let us know in order that we can immediately erase your details from our mailing list. On the other hand, if you are interested in this subject, we are pleased to inform you about our web site address: _www.br13.com_ (http://www.br13.com/) where you can find general information about this research. For more specific research information, with references relating to neurogenesis and also to the aetiology, nutritional and environmental factors concerning MSA and PD, please visit our web site: _www.shydrager.com_ (http://www.shydrager.com/) Every year, we produce a video documentary and printed enclosures, showing the experiences and responses of Parkinson’s disease and MSA sufferers who have followed our neurogenic dietary intervention programme for some time. These documentaries are sent, free of charge, to doctors, caregivers, clinics and also to patients who are really interested in viewing the practical results of this type of research. Please let us know if you would like to receive this material that is available on DVD or VHS, and where it should be sent. Since the year 2002, when we first published the six basic stages on which our Neurogenic Dietary Intervention Programme is based, we have received encouraging feedback from doctors and scientists world-wide. For example, in relation to Stage 1 of the Neurogenic Diet, we received various medical reports indicating that they obtained substantial improvements when a re-adjustment of PD medication was combined with the use of an appropriate nutritional intervention. A number of patients who personally researched Stage 4 of the Neurogenic Diet, came across with findings that led them to the discovery of what was the main causative factor of their own disease. Then, by strictly avoiding further contact with this specific causative agent, they found that their symptoms, that had affected them for years, started now gradually to disappear. Also, a large number of patients benefited when following Stage 6 of The Neurogenic Diet. This relates to the importance of an appropriate exercise programme to allow the enhancement of neuronal regeneration. A number of physical therapists developed special exercise programmes, aiming to enhance neurogenic activity in Parkinson’s disease and in MSA. Soon after, they were able to report that, thanks to this exercise programme, patients were able to reduce their need for their medication by more than 30%. in the year 2002, neuroscientists from our team suggested, that neurogenesis can also occur in the dopaminergic system in the human brain . They observed that Parkinson’s Disease and MSA patients, who followed the neurogenic programme, could gradually delay the use of their first dose of PD medication. Some patients were surprised to see that, instead of needing to start the first dose at 7 am, they were able to function normally, without any medication until 10 am. Later on, they realised they could delay it until 1 pm. Some patients were even able to postpone it until late in the afternoon. This was a very clear indication that these patients had been able to restore their own neuronal capabilities to produce brain neurotransmitters like dopamine, without the need of a direct external source, precursor or dopamine agonist. Now, in 2004, it has finally been confirmed in a number of medical and scientific research publications, that neurogenesis can also take place in dopaminergic neurons in the substantia nigra in the adult mammalian brain. These areas are the main neuronal systems affected in Parkinson’s Disease and MSA-P. The main objective of our research newsletter is the dissemination of scientific information in relation to neurogenesis. We try to present this precious scientific knowledge, in the clearest way, in order that a better understanding about it, be utilised to improve the quality of life of Parkinson’s Disease and MSA sufferers. As an example of one of our previous newsletters and documentaries, we are pleased to enclose below, part of the script of the: "Documentary on Neurogenesis, Year 2003" Thank you for your time Nutritional Medicine Research. _www.br13.com_ (http://www.br13.com/) _www.shydrager.com_ (http://www.shydrager.com/) e-mail: [log in to unmask] 24 Hour Telephone Help Line and Information: In the USA: 520 750 6466 All Other countries: 00-44 7930 915 588 TEXT FROM VIDEO SCRIPT for the Documentary on NEUROGENESIS RESEARCH TITLE: ORIGINAL HOME-VIDEO CLIPS SHOWING THE GENUINE PERSONAL EXPERIENCES OF PARKINSON’S DISEASE AND MSA SUFFERERS. To assess the degrees of neuronal activity which can be induced through a specific type of intervention, the following suggestions are indicated for Parkinson’s disease and MSA patients: 1. –The assessment must be done in the morning. Patients must be free of Parkinson’s disease medication and of any medicinal extract for at least 18 to 24 hours. 2. - To determine the degree of advancement of the disease, find out which movements or activities are the most difficult to perform, before taking the early morning extract or the prescribed PD drugs. 3. - The ability to perform each task needs to be evaluated. This examination measures, for example, the ability to stand up from a chair, getting out of bed, walking, opening doors, dressing, writing, taking a bath, etc. 4. - DNA repair and neuronal regeneration are slow processes therefore, to be able to observe any external changes, the evaluation tests are usually performed at 3 monthly intervals. 5. - The ability to improve performance in any of the above activities will indicate to us the degree in which the neurogenic intervention has succeeded. 6. - Most neurological examinations and disability scales are designed to test the ability of a drug to improve mobility for a limited number of hours, following the taking of a specific drug. Here, instead, we test the ability of a treatment to regenerate Neurons. Therefore, tests need to be taken at a time when no drugs or extracts had been used, whatsoever, for at least 18 hours. 7. – An improvement in the performance of any of the above activities will indicate to us that enrichment in brain transmitter biosynthesis has occurred during sleeping hours. This endogenous enhancement of neurotransmitter biosynthesis can only occur as a result of an increase in the number of active brain dopaminergic neurons. The first patient shown on our video documentary is an 89 year old lady, diagnosed with Parkinson’s disease 4 years ago. A medical history, and report, with further details, is available for doctors interested in receiving additional information on this woman. In 1999 she was diagnosed with Parkinson’s disease and prescribed the drug Sinemet 25/100. She tried it for a short time, soon after; this drug had to be discontinued due a bad reaction to it and to undesirable side effects. In April 1999, she started our neurogenic dietary intervention programme, which resolved efficiently her gait disturbance and did not cause her any side effects at all. After one year of using the neurogenic diet, she was able to walk independently without the aid of a cane. At the time of diagnosis, she suffered from a moderate bradykinesia. One year later, there was no apparent sign of a bradykinetic problem at all. During the second year on the neurogenic diet, she became totally independent in the morning. She was able to prepare breakfast, dress herself and go out for a walk without any assistance. After four years on the neurogenic diet, the disease did not show any progression. Instead, there was an apparent disappearance of many of the initial symptoms that lead to the diagnosis of Parkinson’s disease in 1999. In December 2002, at her fourth year on the neurogenic programme, the woman’ s daughter filmed a tape for us and her doctor to show that her mother was now able to perform exercises which were impossible to do a year earlier. This exercise consists of lying on the floor by herself and lifting herself up from the floor, without assistance. This demonstration was filmed at 10 am. The last time she had taken her extract was the previous day at 6 am, that is, 28 hours earlier. The exercise that this lady managed to perform and showed to us is not only a difficult exercise to perform by any Parkinson’s disease patient, but also by anyone at the age of 89. The exercise that she had done is a difficult exercise for anyone at the age of 89, but particularly for anybody suffering for Parkinson disease. The second patient, presented in this video, had been suffering from Parkinson’s disease for 20 years. She is now 78 years old. She is 11 years younger than the previous patient shown in this video. She took Sinemet 25/100, four to six times a day, during the first 15 years she had the disease. During the period she was taking Sinemet, she had sensitive reactions against it, which made her suffer from a number of side effects, over many years. She started on the neurogenic diet in 1997, that is, almost 5 years ago. When she started our treatment, she had been unable to walk for the previous two years and had to make use of a wheelchair during the day. With the introduction of the neurogenic diet, Sinemet was discontinued and replaced by our extracts. This approach allowed her to obtain improvements in her mobility and the side effects; she had been suffering, gradually disappeared. With the help of the extracts, she was able to perform essential movements without having any form of dyskinesia, freezing episodes and "off periods". However, our treatment could not enhance a proper neurogenic activity, mainly because, being almost all day in a wheelchair, she had not been able to perform any form of exercise or any major muscular activity; these are essential factors needed to activate the processes of neurogenesis. It is important to note that what occurred with this patient, is the opposite of what happened to the 89 year old patient shown previously who has been able to take one hour walks every day. In relation to this, she made the following comment in her home-made video: "If you don’t walk at all, then you can’ t walk." This personal observation represents her feelings after realising that the more she can walk and exercise, the better her mobility. Whenever she stops walking, she realises that it becomes harder to start again. The experiences of these two patients, confirmed to us, that exercise and physical activity are the two main factors required for neurogenic processes to take place. The use of our dietary intervention and extracts can only enhance the process of neurogenesis when the patient is able to perform a certain amount of exercise and physical activity. A number of areas of the brain are affected by MSA. This has led to different varieties of MSA receiving different names, depending on which area of the brain has predominant involvement. When a patient initially has rigidity (stiffness) and slowness in initiating movements (bradykinesia) which is out of proportion to tremour, this MSA form has been called striatonigral degeneration, involving communication between nerve cells in the striatum and midbrain. This is the form of MSA which has been diagnosed to the third patient shown in the video. It is also called MSA-P, because it resembles the symptoms of Parkinson’s disease. This patient was diagnosed two years ago, as having Parkinson’s disease. Soon after, her neurologist realised that she had developed MSA-P. This is a Multiple System Atrophy of the Striatonigral Degeneration Type. The patient was experiencing serious difficulties in breathing, walking, had a very poor balance, dryness of mouth, difficulties in swallowing, intermittent sleep, constipation, and several other symptoms that were making her life almost unbearable. We asked her family to record a video tape for us, to allow us to have a better understanding of her condition and problems. On the 15th of December 2002, she started on the first stage of our neurogenic diet, which concentrates mainly on the replacement of any drugs that might be causing adverse reactions. A few weeks later, as soon as the drugs Sinemet and Amantadine were reduced by 50%, most of the severe symptoms she was experiencing had decreased significantly. The family continued to video tape her over the New Year holidays and, with great surprise, they realised that their mother was showing quick and very dramatic improvements. This important visual testimony helps to demonstrate that, in some instances, the symptoms thought to be of a Parkinson’s disease condition progressing into an MSA condition, might not be the real scenario. Each and every food contains a tiny amount of medicinal substances which help to heal most human diseases. As it is written in Genesis 1.29. "I give you every seed-bearing plant on the face of the whole earth and every tree that has fruit with seed in it. They will be yours for food." Based on this principle we have build up a number of research projects to extract medicinal substances from food. One of this is the medicinal extract RG-40. RG-40 is an organic vegetable extract, rich in amino acids and plant kingdom biological factors, required for the synthesis of neuronal dopamine receptors. RG-40 natural components are organic substances which are easily allowed to penetrate the blood brain barrier and can access the Basal Ganglia, where they interact with the DNA of dopaminergic neurons. RG-40 biological factors are transported inside the dopaminergic neurons reaching the nucleus, where they interact with DNA. DNA in the cell nucleus is the command centre where orders to carry out the synthesis of receptor proteins are executed. Molecular Neurobiology of Dopamine Receptor Synthesis Induced by RG-40. The process begins in the cell nucleus, where RG-40 activates specific genes, which induce DNA to be transcribed into messenger RNA. Messenger RNA then travels to the endoplasmic reticulum where ribosomes cause the messenger RNA to be translated into partially formed dopamine receptor proteins. The next step is for partially formed dopamine receptor proteins to be transformed into complete dopamine receptor molecules in the Golgi Apparatus. Completely formed dopamine receptor molecules are proteins and these are transported to the cell membrane where they interact with the neurotransmitter dopamine. As a result of the interaction between the neurotransmitter dopamine and dopamine receptor molecules, the ability of our muscular system to perform movements is regulated. Neuronal dopamine receptor deficiency causes motor disability problems, such as those observed in conditions like MSA-P and Parkinson's disease. RG-40 PROVIDES THE ORGANIC AMINO ACID PRECURSORS REQUIRED FOR THE SYNTHESIS OF NEURONAL DOPAMINE RECEPTOR MOLECULES. Most drugs available today to treat Parkinson's disease attempt to increase the concentration of the neurotransmitter dopamine or its agonists in areas of the brain which are affected in Parkinson's disease. However, the activity of these drugs is limited by the number of neuronal dopamine receptors available to interact with the neurotransmitter dopamine or its drug agonists. No matter how much a patient increases the dosage of dopamine precursors like Sinemet, or of any of the dopamine agonists drugs, if there are not enough neuronal dopamine receptors to interact with, these drugs will not produce any further response at all. This figure is a schematic diagram of a dopamine receptor showing that it is a protein arranged essentially as a long chain of amino acids. The chain of amino acids, forming the dopamine receptor, winds in and out of the cell several times. This creates three regions of the receptor. Firstly, the extracellular portions are those parts of the chain entirely outside the neuron; secondly, the intracellular portions are those segments of the chain entirely inside the neuron and thirdly, the transmembrane portions, which are the regions of the receptor which reside within the membrane of the neuron. Each and all of the amino acid and biological factors required for the synthesis of this and other dopamine receptor molecules, are present in the organic vegetable extract RG-40, which is now used by all the PD and MSA patients participating in our studies. MSA-C. Olivopontocerebellar atrophy When MSA begins with imbalance, incoordination, and difficulty in speaking (dysarthria), it is called olivopontocerebellar atrophy; as the name suggests, this form of MSA is marked by degeneration in the cerebellum, a structure involved in balance and learned motor tasks. The following patient suffers from this type of MSA, which is also called also MSA-C because the areas affected involve the cerebellum. Patients suffering from MSA-C usually do not show any response to the standard parkinsonian medication. This is precisely the case of the fourth patient presented in this video. She did not show any response to Sinemet. Moreover, she was affected by serious side effects which are not usually present, in the first year, in most of the patients using this drug. We would like to suggest that this patient, as many diagnosed today with MSA, might suffer from a high sensitivity to specific synthetic chemicals. This chemical sensitivity might be a confusing determinant when trying to diagnose the disease. This patient showed rapid improvement, after using a purely organic dietary intervention. We can assume, therefore, that she suffers from a high sensitivity to non-organic chemicals. This suggestion is endorsed by another experience. When this patient started on a clinical trial for a new drug for MSA, she had to drop out at the very beginning of the study, because of adverse reactions and innumerable side effects. Most of the other patients in the trial were not troubled by these side effects. The chemical sensitivity in this patient is higher than normal. For this particular type of patient, who cannot tolerate large doses of drugs, we need to consider prescribing organic interventions with natural products that can help them in a similar way as with the drugs, but without adverse reactions, that can sometimes confuse the diagnosis. The following Parkinson's disease patients, started on our neurogenic programme during 1998. A few months later, he decided to explore other alternatives to treat their disease. He was offered a treatment called: DEEP BRAIN STIMULATION A few months later a deep brain stimulator was implanted in the ventralis intermedius nucleus of the thalamus. The goal of Deep Brain Stimulation is to reduce the activity of overactive brain structures. High-Frequency Electrostimulation inhibits neuronal firing either by depolarisation or by facilitating the action of inhibitory interneurons. The effects of Deep Brain Stimulation are limited to tremor control and drug related dyskinesia. Patients with progressive Parkinson’s disease may eventually become disabled by akinesia and impairment of postural reflexes, requiring more aggressive pharmacotherapy. To find out the long term response to Deep Brain Stimulation on this patient, we contacted him again in July 2002. He told us that initially, he had a good response to Deep Brain Stimulation that lasted for over a year. Gradually, he had to go on increasing the dosages of Sinemet to 8, 10 and 12 times a day. He requested to us, that he would like to go back to using our extracts, to allow a reduction in Sinemet, because it was causing him adverse reactions. We sent him our extract RG-42 and he made a home-video for us, showing how he responded to our extract now, 4 years after a deep brain stimulator had been implanted. We concluded from this experience, as well as from various other similar cases, that patients undergoing Deep Brain Stimulation will not be able to induce neurogenesis or neuronal reactivation in a significant way. Our dietary intervention programme and extracts can only help patients using a Deep Brian Stimulator in a palliative manner, mainly to reduce adverse reactions, appearing after larger dosages of drugs have to be gradually reinstated. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn